Medical Devices
Home » Needle Free Diabetes Management Market

Needle Free Diabetes Management Market By Device Type (Insulin Jet Injector, Insulin Pen, Insulin Inhaler, and Insulin Patch & Pump) – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2022

Price: $4999

Published: | Report ID: 14430 | Category: Medical Devices

Market Insights

This report, titled “Needle-Free Diabetes Management Market,” studies various device types such as treatment devices, diagnostic devices, and artificial pancreas that are respectively sub-segmented. According to the International Diabetes Federation, in 2015, one in 11 adults had diabetes, and by 2040, it is expected that one in 10 adults will have diabetes. The data suggests that in 2015, every six seconds, one person died from diabetes. Thus, diabetes management is one of the most crucial parts of preventing the life-threatening effects of this disease. The ongoing research and development activities in the field of diagnosis and treatment of diabetes are expected to change the market’s aspect in the coming years.

For the purpose of this study, the global market for needle-free diabetes management is segmented on the basis of device type into treatment devices, diagnostic devices, and artificial pancreas. Treatment devices comprise insulin pens, pumps and patches, inhalers, and jet injectors. Diagnosis devices are further sub-segmented as continuous glucose monitoring (CGM) devices and flash glucose monitoring (FGM) systems. Market size estimates and forecasts for these segments for the period 2013–2022 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2016–2022, considering 2015 as the base year.

The needle-free diabetes management market has been geographically categorized into major regions such as North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, and the GCC countries. The market size and forecast for these segments during 2013–2022 and their CAGRs for the period 2016–2022 are provided in this report.

The major key players profiled in the needle-free diabetes management market are based on various characteristics such as business description, financial health, budget allocation, product portfolio, and news coverage. The key players profiled in this report are Zogenix, Inc., 3M, Antares Pharma Inc., Glide Pharmaceutical Technologies Ltd., Injex Pharma AG, Pharmajet, Inc., Bioject Medical Technologies, Inc., Medtronic, Inc., Johnson & Johnson, Inc., Pancreum LLC, Tandem Diabetes Care, Inc., JDRF, and Akra Dermojet.

Based on the type of devices, the global needle-free diabetes management market is segmented as follows:

Treatment Devices

  • Insulin jet injector
  • Insulin Pen
  • Insulin Inhaler
  • Insulin Patch and Pump

Diagnostic Devices

  • Continuous Glucose Monitoring (CGM) System
  • Flash Glucose Monitoring (FGM) System
  • Artificial Pancreas

In the base year of 2015, insulin patches and pumps were observed as the fastest-growing segment in the treatment devices segment due to their high efficiency, patient convenience, and rising public awareness related to the novel needle-free treatment devices. Insulin pens and jet injectors collectively accounted for the largest market share of around 51% of the overall needle-free diabetes treatment market as they are one of the most initial treatment solutions available in the market, have achieved high market penetration to date, and have high public awareness related to the products.

Flash glucose monitoring systems are considered the most novel diabetes monitoring devices after CGM. Abbott Laboratories introduced the first flash glucose monitoring system, FreeStyle Libre, to the market in February 2016, which received the European CE mark. The FreeStyle Libre flash glucose monitoring system, which is available in several European countries, is designed to change how people with diabetes measure their glucose levels and ultimately help them achieve better health outcomes. The system reads glucose levels through a sensor that is worn on the back of the upper arm for up to 14 days, eliminating the need for routine finger pricks. In addition, no finger prick calibration is considered a key differentiating property compared to current continuous glucose monitoring systems.

An artificial pancreas system comprises a continuous glucose monitor (CGM) and a continuous subcutaneous insulin infusion pump, both of which are available on the market today, and a controller linking the monitor and pump and running a highly sophisticated algorithm to determine the appropriate amount of insulin to deliver and the timing for that delivery based on evaluation of real-time glucose readings. Such systems are expected to mimic the functions of a healthy pancreas by blending continuous glucose monitoring, remote-controlled insulin pumps, and artificial intelligence to maintain healthy blood sugar levels automatically.

For the purpose of this study, the global market for needle-free diabetes management is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

In the base year 2015, North America was observed as the largest and most potential regional market for the needle-free diabetes management market. North America comprises the regional markets of the U.S. and Canada, and the rising prevalence of diabetes is the major driver for the growth of the needle-free diabetes management market in North America. The developed healthcare infrastructure, high public awareness related to diabetes management, and rising research and development activities related to diabetes management are the key factors assisting the growth of the North American needle-free diabetes management market. According to International Diabetes Federation (IDF) reports, approximately 382 million people globally were diagnosed with diabetes in 2013, and this number is expected to grow to 592 million by 2035.

Asia Pacific is expected to be the fastest-growing regional market for needle-free diabetes management by 2022. Over the next six years, the growth of the market in the Asia-Pacific region is likely to be centered in Japan, South Korea, China, and India. Numerous factors, such as the developing economic landscape and industrialization, increasing disposable incomes, growing public awareness related to diabetes management, and mounting diagnostic rates that provide favorable environments for glucose monitoring devices, are expected to contribute significantly to the growth of the Asia-Pacific market.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Needle Free Diabetes Management Market, by Devices Type, 2015 v/s 2022 (Value %)
2.2 Global Needle Free Diabetes Management Market, by Geography, 2015 (Value %)

Chapter 3 Global Needle Free Diabetes Management Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Increasing Prevalence Of Diabetes Due To Mounting Obesity And Sedentary Lifestyle In People
3.2.2 Growing Evolution and Success of Continuous Glucose Monitors
3.3 Market Restraints
3.3.1 Creating Quick Acting Insulin and Glucagon Formula
3.3.2 Regulatory Hurdles and Cost Constraints
3.4 Market Opportunities
3.4.1 Development of Next Generation Glucose Sensors
3.4.2 Intensive Investment in R&D Efforts
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Needle Free Diabetes Management, by Key Players
3.6.1 Needle Free Diabetes Management Market, Key Players Analysis By Treatment Devices
3.6.2 Needle Free Diabetes Management Market, Key Players Analysis By Diagnostic Devices

Chapter 4 Global Needle Free Diabetes Management Market Analysis, By Device Type
4.1 Overview
4.2 Treatment Devices
4.2.1 Insulin Jet Injector
4.2.2 Insulin Pen
4.2.3 Insulin Inhaler
4.2.4 Insulin Patch & Pump
4.3 Diagnostic Devices
4.3.1 Continuous Glucose Monitoring (CGM) System
4.3.2 Flash Glucose Monitoring (FGM) System
4.4 Artificial Pancreas Devices & Systems

Chapter 5 Global Needle Free Diaabetes Managements Transplantion Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S.
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 Japan
5.4.2 China
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.5.1 Brazil
5.5.2 Mexico
5.5.3 Rest of Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 Zogenix, Inc.
6.1.1 Zogenix, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.2 3M
6.2.1 3M: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.3 Antares Pharma Inc.
6.3.1 Antares Pharma Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.4 Glide Pharmaceutical Technologies Ltd.
6.4.1 Glide Pharmaceutical Technologies Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.5 Injex Pharma AG
6.5.1 Injex Pharma AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.6 Pharmajet, Inc.
6.6.1 Pharmajet, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.7 Bioject Medical Technologies, Inc.
6.7.1 Bioject Medical Technologies, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.8 Medtronic, Inc.
6.8.1 Medtronic, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.9 Johnson & Johnson, Inc.
6.9.1 Johnson & Johnson, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.10 Pancreum LLC
6.10.1 Pancreum LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.11 Tandem Diabetes Care, Inc.
6.11.1 Tandem Diabetes Care, Inc..: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.12 JDRF
6.12.1 JDRF: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.13 Akra Dermojet
6.13.1 Akra Dermojet: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List of Figures

FIG. 1 Needle Free Diabetes Management Market: Research Methodology
FIG. 2 Global Needle Free Diabetes ManagementMarket, by Device Type, 2015 v/s 2022 (Value %)
FIG. 3 Global Needle Free Diabetes ManagementMarket, by Geography, 2015 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2015
FIG. 5 Needle Free Diabetes Management Market, Key Players Analysis By Treatment Devices
FIG. 6 Needle Free Diabetes Management Market, Key Players Analysis By Treatment Devices
FIG. 7 Insulin Jet Injectors Market for Diabetes Management, 2014 – 2022 (USD Mn)
FIG. 8 Insulin Pens Market for Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 9 Insulin Inhalers Market for Diabetes Management, 2014 – 2022 (USD Mn)
FIG. 10 Insulin Patch & Pump for Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 11 Continuous Glucose Monitoring (CGM) System Market for Diabetes Management, 2014 – 2022 (USD Mn)
FIG. 12 Flash Glucose Monitoring (FGM) System Market for Diabetes Management Market, 2015 – 2022 (USD Mn)
FIG. 13 Artificial Pancreas Devices & Systems Market for Diabetes Management Market for Lymphoproliferative Disorders, 2014 – 2022 (USD Mn)
FIG. 14 U.S. Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 15 Canada Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 16 U.K Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 17 Germany Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 18 Rest of Europe Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 19 Japan Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 20 China Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 21 Rest of Asia Pacific Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 22 Brazil Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 23 Mexico Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 24 Rest of Latin America Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)
FIG. 25 Middle East & Africa Needle Free Diabetes Management Market, 2014 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Needle Free Diabetes Management Market, by Devices, 2014-2022 (USD Mn)
TABLE 2 Global Needle Free Diabetes Management Market, by Treatment Devices, 2016 – 2022 (USD Mn)
TABLE 3 Global Needle Free Diabetes Management Market, by Diagnostic Devices, 2016 – 2022 (USD Mn)
TABLE 4 Zogenix, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 5 3M: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 6 Antares Pharma Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 Glide Pharmaceutical Technologies Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 Injex Pharma AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 9 Pharmajet, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 10 Bioject Medical Technologies, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 11 Medtronic, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 12 Johnson & Johnson, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 13 Pancreum LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 14 Tandem Diabetes Care, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 15 JDRF: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 16 Akra Dermojet: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

Frequently Asked Question:

What is the size of Needle Free Diabetes Management Market?

The market for Needle Free Diabetes Management Market is expected to reach USD$ 592 million in 2022.

What is the Needle Free Diabetes Management Market CAGR?

The Needle Free Diabetes Management Market is expected to see significant CAGR growth over the coming years, at XX%.

What is the Forecast period considered for Needle Free Diabetes Management Market?

The report is forecasted from 2016 -2022.

What is the base year considered for Needle Free Diabetes Management Market?

The base year of this report is 2015.

Who are the major players in this market?

Antares Pharma Inc., Glide Pharmaceutical Technologies Ltd., Injex Pharma AG, Pharmajet, In .are some of the major players in the global market.

Medical Devices

Artificial Cornea and Corneal Implant Market

Published:
Report ID: 30526

Medical Devices

South Africa Prefilled Syringes Market

Published:
Report ID: 30474

Medical Devices

Limb Prosthetics Market

Published:
Report ID: 23452

Medical Devices

Automated Sample Digestion Systems Market

Published:
Report ID: 23335

Medical Devices

Lung Biopsy Systems Market

Published:
Report ID: 22976

Medical Devices

Shock Wave Therapy Market

Published:
Report ID: 22584

Medical Devices

Single Use Flexible Endoscope Market

Published:
Report ID: 22586

Medical Devices

ENT Devices Market

Published:
Report ID: 4694

Medical Devices

Diabetes Drugs Market

Published:
Report ID: 4199

Medical Devices

Endodontic Devices Market

Published:
Report ID: 4444

Medical Devices

Clinical Laboratory Tests Market

Published:
Report ID: 22153

Medical Devices

Blood Bag Tube Sealers Market

Published:
Report ID: 22245

Purchase Options

Buy With Trust, Competitive Pricing - In-depth Analysis

$2999

Delivery Format: Excel.

$4999

Designed for the individual purchaser.

$6999

Users located at a single corporate site or regional office.

$9999

Allowed for unlimited sharing globally within one company.


Still Not Sure?

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN
WhatsApp Now